Dr. George Poste of Arizona State University to be honored with the AZBio Pioneer Award for Lifetime Achievement

Chandler, Arizona —-The Arizona Bioindustry Association will honor Dr. George Poste of Arizona State University with the AZBio Pioneer Award for Lifetime Achievement at the 2016 AZBio Awards.  Governor Doug Ducey and hundreds of Arizona life science and business leaders as well as guests from across the country will be on hand to applaud Dr. Poste for a body of work that has made life better for people at home and around the world.Continue reading

Governor Doug Ducey will address Arizona’s Life Science Innovation Community at the Peak of Arizona Bioscience Week during the 11th Annual AZBio Awards.

 

Chandler, Arizona –September 6, 2016–The Arizona Bioindustry Association (AZBio) today announced that Arizona Governor Doug Ducey will address the life science, education, and business leaders assembled to celebrate the 11th annual AZBio Awards on September 21, 2016 at the Phoenix Convention Center.Continue reading

Avery Therapeutics Awarded NIH SBIR

Avery Therapeutics, Inc., a pre-clinical stage company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, has been awarded a $483k SBIR grant from the National Institutes of Health to develop manufacturing, cryopreservation, storage and reconstitution methods for Avery’s first product MyCardia™. Continue reading

Marni Landry of the Paradise Valley High School CREST Program Named Arizona Bioscience Educator of the Year

The Arizona Bioindustry Association has named Marni Landry, BS, M.Ed of Paradise Valley High School as the 2016 Michael A. Cusanovich Bioscience Educator of the Year in recognition of her dedication  in the classroom and her commitment  to designing  bioscience education programs and curriculum to help inspire and create tomorrow’s bioscience leaders.Continue reading

Insys Therapeutics Announces First Patient Enrolled in Phase II Trial for the Treatment of Cocaine Dependence Using Pharmaceutical Cannabidiol

Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol (CBD) product candidate. The study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of Montreal Hospital Research Center (CRCHUM) and is supported by the Canadian Institutes of Health Research (CIHR) and the Company.Continue reading